ImmuneSensor Therapeutics: Funding, Investors & Team (Oct 2026)
ImmuneSensor is developing novel medicines that target the cGAS (cyclic GMP-AMP synthase) - STING (stimulator of interferon genes) pathway of the innate immune system to treat cancer and autoimmune diseases. The Company has licensed technologies from the laboratory of Dr. Zhijian "James" Chen, Professor of Molecular Biology at the University of Texas Southwestern Medical Center and Investigator of Howard Hughes Medical Institute. Dr. Chen discovered cGAS and its product cGAMP, which activates STING to stimulate immune responses. These discoveries form the technological foundation of ImmuneSensor. The company's pipeline consists of both STING activators to boost anticancer immunity and also cGAS inhibitors to suppress overactivated autoimmunity. ImmuneSensor's lead program, IMSA101 is a STING activator currently in clinical development for cancer therapy.
ImmuneSensor Therapeutics has raised $26.1M across 2 funding rounds on record, the most recent an undisclosed round of $10.0M announced in Dec 2022.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
ImmuneSensor Therapeutics Company Profile and Key Stats
Latest funding round on record: Dec 2022.
ImmuneSensor Therapeutics Funding Rounds
ImmuneSensor Therapeutics raised $16.1M in a Grant announced in Sep 2022.
3 months later, an undisclosed round of $10.0M was announced in Dec 2022.
ImmuneSensor Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
ImmuneSensor Therapeutics Funding Compared to Other Biotechnology Startups
ImmuneSensor Therapeutics' latest round of $10.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like ImmuneSensor Therapeutics in Biotechnology and Dallas
Companies Similar to ImmuneSensor Therapeutics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
ImmuneSensor Therapeutics Funding FAQs
What does ImmuneSensor Therapeutics do?
ImmuneSensor is developing novel medicines that target the cGAS (cyclic GMP-AMP synthase) - STING (stimulator of interferon genes) pathway of the innate immune system to treat cancer and autoimmune diseases. The Company has licensed technologies from the laboratory of Dr. Zhijian "James" Chen, Professor of Molecular Biology at the University of Texas Southwestern Medical Center and Investigator of Howard Hughes Medical Institute. Dr. Chen discovered cGAS and its product cGAMP, which activates STING to stimulate immune responses. These discoveries form the technological foundation of ImmuneSensor. The company's pipeline consists of both STING activators to boost anticancer immunity and also cGAS inhibitors to suppress overactivated autoimmunity. ImmuneSensor's lead program, IMSA101 is a STING activator currently in clinical development for cancer therapy.
How much funding has ImmuneSensor Therapeutics raised?
ImmuneSensor Therapeutics has raised $26.1M across 2 rounds on record. The most recent is an undisclosed round of $10.0M announced in Dec 2022.
When did ImmuneSensor Therapeutics last raise funding?
ImmuneSensor Therapeutics' most recent funding round on record is an undisclosed round of $10.0M, announced in Dec 2022.
Who founded ImmuneSensor Therapeutics?
FundedIQ lists Qingsong Jet Li (Founder) at ImmuneSensor Therapeutics.
Where is ImmuneSensor Therapeutics headquartered?
ImmuneSensor Therapeutics is based in Dallas, Texas, United States.
How many employees does ImmuneSensor Therapeutics have?
ImmuneSensor Therapeutics is in the 1-10 employee band.
How does ImmuneSensor Therapeutics' funding compare to other Biotechnology startups?
ImmuneSensor Therapeutics' latest round of $10.0M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's ImmuneSensor Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for ImmuneSensor Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.